Drugs / Nafarelin
Nafarelin
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | SYNAREL | — | 1998-12-24 | fda.gov ↗ |
| Approved | US (FDA) | SYNAREL | — | 1990-02-13 | fda.gov ↗ |
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00034047 | Sep 2002 → Aug 2006 | endometriosis, pelvis syndrome | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04850261 | May 2021 → Mar 2024 | infertility disorder | Insel Gruppe AG, University Hospital Bern | Withdrawn | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06150703 | Jun 2024 → Sep 2027 expected | — | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02865681 | Jul 2016 → Jun 2017 | infertility disorder | New Hope Fertility Center | Completed | No outcome recorded |
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06870266 Comparator | Mar 2025 → Mar 2027 expected | — | Shaare Zedek Medical Center | Not yet recruiting | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT06763926 Comparator | Jun 2026 → Jan 2028 expected | — | Fundacion Dexeus | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04797338 Comparator | Dec 2017 → Sep 2021 | ovarian hyperstimulation syndrome, pregnancy disorder with abortive outcome | Assaf-Harofeh Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT00843570 Comparator | Nov 2009 → May 2013 | infertility disorder | University of Oxford | Completed | No outcome recorded |
| Phase 4 | NCT00756028 Comparator | Jan 2009 → Dec 2014 | infertility disorder, ovarian hyperstimulation syndrome | Peter Hornnes, MD, DMSc | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nafarelin | “When at least two follicles reached 18 mm or greater, Synarel (Nafarelin) will be used instead of the injectable HCG trigger.” NCT02865681 ↗6“Intervention pharmacon: GnRH-agonist (Synarela®:Nafarelin)” NCT00756028 ↗ |
| Known as | Nafarelin acetate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00843570 ↗ |
| Known as | Synarel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02865681 ↗ |
| Known as | Synarela | “Intervention pharmacon: GnRH-agonist (Synarela®:Nafarelin)” NCT00756028 ↗ |
| Action | Activate | “gonadotropin releasing hormone agonist (GnRHa)” NCT00034047 ↗ |
| Modality | Other / unclassified | “GnRH agonist treatment” NCT06870266 ↗ |
| Route | Intranasal | “via intranasal spray” NCT00034047 ↗ |